RxDoctor Payments Data

Marshall Hall, MD

Urology · Rockport, MENPI 1881676484

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $542 and has fallen 82.7% since, to $94 in 2025. That places this record below the midpoint for urology clinicians in ME, where the typical reported total is $1,024.

$738in general payments, 2019–2025

Across 35 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$164
  • Johnson & Johnson$94
  • Boston Scientific$80
  • Bayer$65
  • Teleflex LLC$64
  • Pfizer$48
  • plus $222 from 9 others

What the payments were for

  • Food & beverage$738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$738 in reported general payments places this provider in the 40th percentile of 59 urology providers in Maine.

See all urology providers in Maine

Medicare billing

Part B allowed, 2024
$20,327
Medicare patients
80
Services billed
189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron12$12,631
Silodosin51$4,123
Solifenacin Succinate47$3,236
Finasteride252$3,106
Tamsulosin Hcl191$2,418
Estradiol21$1,176
Cefdinir21$294
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim30$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$23$12,63112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 59 urology providers in Maine.

Other urology in Rockport

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →